Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
12 hedge funds and large institutions have $264K invested in Aptose Biosciences, Inc. in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
20% more funds holding
Funds holding: 10 → 12 (+2)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
80% less capital invested
Capital invested by funds: $1.34M → $264K (-$1.08M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$46.3K |
| 2 |
US Bancorp
Minneapolis,
Minnesota
|
+$45K |
| 3 |
Jane Street
New York
|
+$19.5K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$16.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.34K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.22M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$5.37K |
| 3 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$4.03K |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
-$2.69K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.34K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $54K | +$46.3K | +69 | +575% |
|
2
Renaissance Technologies
New York
| $46K | – | – | – |
|
|
3
US Bancorp
Minneapolis,
Minnesota
| $45K | +$45K | +67 | New |
|
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| $43K | -$1.34K | -2 | -3% |
|
|
5
Bank of Montreal
Toronto,
Ontario, Canada
| $22K | -$5.37K | -8 | -20% |
|
|
6
Jane Street
New York
| $19K | +$19.5K | +29 | New |
|
|
7
Acadian Asset Management
Boston,
Massachusetts
| $16K | +$16.1K | +24 | New |
|
|
FDCDDQ
8
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $9.59K | -$4.03K | -6 | -29% |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $4K | -$1.34K | -2 | -33% |
|
|
10
UBS Group
Zurich,
Switzerland
| $3K | +$1.34K | +2 | +67% |
|
|
11
Parallax Volatility Advisers
San Francisco,
California
| $2K | -$2.69K | -4 | -57% |
|
|
CAM
12
Cormorant Asset Management
Boston,
Massachusetts
| – | -$1.22M | -2,201 | Closed |
|
13
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$671 | -1 | Closed |
|
14
Bank of America
Charlotte,
North Carolina
| – | +$671 | +1 | New |
|
APTO Hedge Fund Activity: Q3 2017 in Review
12 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q3 2017, worth a combined $264K — down 80% from $1.34M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new APTO positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 5 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $46.3K. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $1.22M sold.
- 12 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q3 2017, up from 10 in Q2 2017.
- Funds reported $264K of Aptose Biosciences, Inc. stock for Q3 2017, down 80% quarter-over-quarter.
- 4 funds opened new Aptose Biosciences, Inc. positions in Q3 2017 and 2 closed out, a net change of +2 holders.
- The largest Aptose Biosciences, Inc. buyer in Q3 2017 was Morgan Stanley, an estimated $46.3K added.
- The largest Aptose Biosciences, Inc. seller in Q3 2017 was Cormorant Asset Management, an estimated $1.22M sold.
Based on aggregated 13F filings for Q3 2017.